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Introduction
Th   e phosphatidylinositol 3-kinase (PI3K) pathway is the 
most frequently mutated pathway in breast cancer, with 
mutation and/or ampliﬁ  cation of the genes encoding the 
PI3K catalytic subunits p110α (PIK3CA) and p110β 
(PIK3CB), the PI3K regulatory subunit p85α (PIK3R1), 
receptor tyrosine kinases (RTKs) such as human epider-
mal growth factor receptor (HER)2 (ERBB2) and ﬁ  bro-
blast growth factor receptor (FGFR)1, the PI3K activator 
K-Ras, the PI3K eﬀ  ectors AKT1, AKT2, and phospho-
inositide-dependent kinase 1 (PDK1), and loss of the lipid 
phosphatases PTEN (phosphatase and tensin homo  log) 
and INPP4B (inositol polyphosphate-4-phosphatase, type 
II) (Table 1). PI3K is activated by growth factor RTKs and 
G-protein-coupled receptors (Figure 1). PI3K phosphory-
lates phosphatidylinositol 4,5-bisphosphate (PIP2) to 
produce phosphatidylinositol 3,4,5-trisphosphate (PIP3). 
In turn, PIP3 recruits to the plasma membrane several 
pleckstrin homology (PH) domain-containing proteins, 
such as PDK1 and AKT, which, upon activation, drive cell 
cycle progression and survival. Negative regulation of 
this pathway is conferred by PTEN and INPP4B, which 
dephosphorylate PIP3 and PIP2, respectively. Akt phos-
phory  lates and inactivates Tuberin (TSC2), a GTPase-
activating protein of the Ras homologue Rheb. Inactiva-
tion of Tuberin allows GTP bound-Rheb to accumulate 
and activate the mammalian target of rapamycin 
(mTOR)/Raptor (TORC1) complex, which ultimately 
regulates protein synthesis and cell growth [1]. mTOR 
also couples with Rictor to form the TORC2 complex, 
which phosphorylates and activates AKT at Ser473.
Class IA PI3K isoforms are heterodimeric lipid kinases 
that contain a p110 catalytic subunit and a p85 regulatory 
subunit. Th  e  three  genes  PIK3CA, PIK3CB, and PIK3CD
encode the homologous p110α, p110β, and p110δ iso-
zymes, respectively. Expression of p110δ is largely 
restricted to immune and hematopoietic cells, whereas 
p110α and p110β are ubiquitously expressed. PIK3CA 
mutations are the most common genetic alterations of 
this pathway in breast cancer, where ≥80% occur within 
the helical (E542K and E545K) and kinase (H1047R) 
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resistance to HER2-targeted therapies. In experimental 
models of resistance to anti-estrogens and HER2 
inhibitors, pharmacological inhibition of PI3K/AKT/
mTOR has been shown to overcome drug resistance. 
Early clinical data suggest that combined inhibition 
of either HER2 or ER plus inhibition of the PI3K 
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catalytic activity through diﬀ  erent mechanisms [2], but 
both induce characteristics of cellular transformation, 
including growth factor- and anchorage-independent 
growth, and resistance to anoikis [3]. Temporally regu-
lated expression of the H1047R mutant in the mammary 
gland of transgenic mice induces mammary tumor 
formation [4]. Genetic or pharmacological inactivation of 
PIK3CAH1047R expression results in disappearance of 
mammary tumors. However, some of these recur and 
become insensitive to PI3K inhibition via c-myc 
overexpression [5].
PI3K pathway alterations frequently co-occur in breast 
cancer, suggesting that they confer advantages to cancer 
cells by diﬀ   erent mechanisms. For example, PIK3CA 
mutations sometimes occur in breast tumors harboring 
PTEN loss or HER2 overexpression [6-8]. p110α is essen-
tial for signaling and growth of tumors driven by PIK3CA 
mutations, RTKs, and/or mutant Ras, whereas p110β lies 
downstream of G-protein-coupled receptors and has 
been shown to mediate tumorigenesis in PTEN-deﬁ  cient 
cells [9]. HER2 overexpression and PIK3CA mutations 
are commonly found in both ductal carcinoma in situ 
and invasive breast cancers. However, PIK3CA mutations 
are found at a lower frequency in intraepithelial neo-
plastic lesions. Th   is suggests that PIK3CA mutations can 
further augment PI3K pathway activation mediated by 
other oncogenes such as ERBB2 (HER2) [10-14].
Molecular analyses have shown that breast cancer is a 
collection of diseases that generally ﬁ  t into three subtypes 
that respond to diﬀ   erent therapeutics and exhibit a 
diﬀ   erent natural history. Breast cancers that express 
estrogen receptor α (ER) and/or progesterone receptor 
(PR) are hormone-dependent and, as such, respond to 
therapies that inhibit ER signaling by multiple mecha-
nisms. HER2-positive cancers exhibit ampliﬁ  cation  or 
overexpression of the ERBB2  (HER2) proto-oncogene 
and respond clinically when treated with HER2-directed 
therapies. Triple-negative breast cancers (TNBCs), which 
lack detectable expression of ER, PR, and HER2, have no 
approved targeted therapy and are treated with 
traditional chemotherapy. Th  erefore, we will separately 
Table 1. Phosphatidylinositol 3-kinase pathway alterations in human breast cancers by molecular subtype
  Frequency
Gene (protein)  Alteration  Eff  ect on signaling  Luminal (ER+)  HER2+  Basal (TN)  Reference
ErbB2 (HER2) Gene amplifi  cation or 
overexpression
Hyperactivation of ErbB2 
signaling (PI3K, MEK)
10% ~100% 0% [30-32]
PTEN Loss-of-function 
mutation or reduced 
expression
Hyperactivation of PI3K 
signaling
29-44% 22% 67% [6,8,104,105]
PIK3CA (p110α/PI3K) Activating mutation Hyperactivation of PI3K 
signaling
28-47% 23-33% 8-25% [6,52,66-68, 
105-107]
PIK3CB (p110β/PI3K) Amplifi  cation Unknown 5% of all cases [62]
IGF1R and INSR (IGF-1R, 
InsR)
Receptor activation, 
IGF1R amplifi  cation
Activates IGF-IR/InsR signaling 
(PI3K, MEK)
41-48% 18-64% 42% [108,109]
FGFR1 Amplifi  cation, activating 
mutation
Hyperactivation of FGFR 
signaling (PI3K, MEK)
8.6-11.6% 5.4% 5.6% [63,110]
RPS6K1 (p70S6K) Amplifi  cation Unknown 3.8-12.5% of all cases [111]
INPP4B Reduced expression or 
genomic loss
Hyperactivation of PI3K 
signaling
10-33% 54% 53% [64,112]
PIK3R1 (p85α/PI3K) Inactivating mutation Derepression of catalytic activity 
of p110α
2% of all cases [113]
AKT1 Activating mutation Hyperactivation of AKT  2.6-3.8% 0% 0% [65,66,
106,114]
AKT2 Amplifi  cation Hyperactivation of AKT  2.8% of all cases [115]
EGFR Amplifi  cation Hyperactivation of EGFR 
signaling (PI3K, MEK)
0.8% of all cases [116]
PDK1 Amplifi  cation or 
overexpression
Hyperactivation of PDK1 (AKT, 
TORC1)
22% 22% 38% [117]
KRAS Activating mutation Hyperactivation of PI3K and MEK 4-6% of all cases [118,119]
EGFR, epidermal growth factor receptor; ER, estrogen receptor; FGFR, fi  broblast growth factor receptor; HER, human epidermal growth factor receptor; IGF-1R, insulin-
like growth factor-1 receptor; INPP4B, inositol polyphosphate-4-phosphatase, type II; InsR, insulin receptor; MEK, mitogen-activated protein kinase kinase; PDK1, 
phosphoinositide-dependent kinase 1; PI3K, phosphatidylinositol 3-kinase; TN, triple negative.
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pathway in each breast cancer subtype and their clinical 
implications.
PI3K pathway inhibitors in clinical development
Several drugs targeting multiple levels of the PI3K 
network (that is, PI3K, AKT, mTOR) are in clinical 
development in breast cancer. Th  e ﬁ  rst group encom-
passes ATP mimetics that bind competitively and 
reversibly to the ATP-binding pocket of p110; some of 
these compounds also bind and inhibit mTOR (Table 2). 
Notably, the pan-PI3K and p110α-speciﬁ  c inhibitors are 
equally potent against oncogenic mutants of p110α 
[15,16]. A second group includes allosteric and ATP-
competitive inhibitors of the three isoforms of AKT; 
these have also shown antitumor activity in preclinical 
models [17-19] and recently entered human trials. Allo-
steric inhibitors such as MK-2206 bind to the PH domain 
and/or hinge region in AKT to promote an inactive 
conformation and thus prevent localization (and activa-
tion) of AKT to the plasma membrane [19]. Th  e  macro-
lide rapamycin and its analogs (rapalogs) complex with 
FK506-binding protein (FKBP12), which then binds to 
mTOR and inhibits the kinase activity of TORC1 but not 
TORC2 [20]. Formulation problems with rapamycin and 
its inability to eﬀ   ectively inhibit phosphorylation of 
4E-BP proteins (which are TORC1 substrates that 
promote translation) prompted the development of 
analogs that have shown cytostatic activity in preclinical 
models and clinical trials [20]. Compounds that target 
Figure 1. Diagram of the phosphatidylinositol 3-kinase signaling pathway. Tumor promoters and suppressors are labeled in pink and blue, 
respectively. Nodes targeted by drugs in clinical development are shown in red. AMPK, AMP-activated protein kinase; GPCR, G-protein-coupled 
receptor; GSK3, glycogen synthase kinase 3; INPP4B, inositol polyphosphate-4-phosphatase, type II; LKB1, liver kinase B1; PDK1, phosphoinositide-
dependent kinase 1; PI3K, phosphatidylinositol 3-kinase; PIP1, phosphatidylinositol monophosphate; PIP2, phosphatidylinositol 4,5-bisphosphate; 
PIP3, phosphatidylinositol 3,4,5-trisphosphate; PTEN, phosphatase and tensin homolog; RTK, receptor tyrosine kinase.
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against both TORC1 and TORC2 [21], are also in phase I 
trials.
Inhibition of TORC1 relieves negative feedback on 
activators of PI3K (for example, insulin-like growth 
factor-1 receptor (IGF-1R), insulin receptor substrate 1 
(IRS-1), HER3) [22-24], suggesting that direct inhibitors 
of PI3K may be more eﬀ  ective. However, inhibition of 
PI3K or AKT also results in feedback upregulation/
activation of several RTKs, which, by providing an input 
to PI3K, may counter  act drug action and/or activate 
other oncogenic pathways such as the mitogen-activated 
protein kinase kinase (MEK) pathway [17,25-27]. Th  ese 
data suggest that PI3K/AKT/TORC1 inhibitors could be 
combined with RTK inhibitors to induce an optimal 
antitumor eﬀ  ect. Consistent with this notion, studies in 
human cancer xenografts have shown that combinations 
of inhibitors targeting HER2 and PI3K, HER2 and AKT, 
HER2 and TORC1, or epidermal growth factor receptor 
(EGFR) and AKT are superior to single-agent treatments 
[17,22,25,26].
PI3K pathway alterations in ER+ breast cancer
Approximately 75% of primary breast cancers express ER 
and/or PR. Such hormone receptor expression typically 
indicates a degree of estrogen dependence for cancer cell 
growth. Treatments for these patients inhibit ER function 
either by antagonizing ligand binding to ER (tamoxifen 
and other selective estrogen receptor modulators 
(SERMs)), downregulating ER (fulvestrant), or blocking 
estrogen biosynthesis (aromatase inhibitors (AIs)). 
Although endocrine therapies have changed the natural 
Table 2. Phosphatidylinositol 3-kinase pathway inhibitors in clinical development
Kinase target  Drug  Manufacturer  Mechanism of action
Pan-PI3K BKM120  Novartis  ATP-competitive
 XL-147  Exelixis  ATP-competitive
 PX-866  Oncothyreon  ATP-competitive
 GDC-0941  Genentech/Roche  ATP-competitive
 CH5132799  Chugai  Pharma  ATP-competitive
p110δ-specifi  c  CAL-101  Calistoga  ATP-competitive
p110α-specifi  c  BYL719  Novartis  ATP-competitive
 GDC-0032  Genentech/Roche  ATP-competitive
 INK-1117  Intellikine  ATP-competitive
PI3K/mTOR PKI-587  Pfi   zer  ATP-competitive
 BEZ235  Novartis  ATP-competitive
 BGT226  Novartis  ATP-competitive
 PF-4691502  Pfi   zer  ATP-competitive
 GDC-0980  Genentech/Roche  ATP-competitive
 XL-765  Exelixis  ATP-competitive
 SF1126  Semafor  ATP-competitive/peptide-conjugate
 GSK1059615  GSK  ATP-competitive
TORC1  Everolimus (RAD001)  Novartis  Indirect, FKBP12-mediated
  Temsirolimus (CCI-779)  Wyeth/Pfi  zer  Indirect, FKBP12-mediated
  Ridaferolimus (AP-23573)  Merck/Ariad  Indirect, FKBP12-mediated
TORC1/TORC2 INK-128  Intellikine  ATP-competitive
 OSI-027  OSI  Pharm.  ATP-competitive
 AZD-8055  Astrazeneca  ATP-competitive
AKT AZD5363  Astrazeneca  ATP-competitive
 GDC-0068  Genentech/Roche  ATP-competitive
 GSK690693  GSK  ATP-competitive
 MK-2206  Merck  Allosteric
 VQD002  Vioquest  ATP-competitive
mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol 3-kinase.
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patients with early ER+ breast cancer relapse within 
15 years following adjuvant therapy with tamoxifen, and 
approximately 20% of patients treated with an AI relapse 
within 9 years [28,29]. A mechanism of resistance to 
endocrine therapy involves overexpression of HER2 
[30-32]. However, <10% of ER+ breast cancers express 
high HER2 levels, suggesting that for the majority of ER+ 
breast cancers, mechanisms of escape from endocrine 
therapy remain to be elucidated.
In addition to its pro-survival and growth-promoting 
roles, the PI3K pathway interacts with ER directly [33] 
and indirectly. ER phosphorylation at Ser167 by AKT or 
p70S6K increases estrogen-induced, tamoxifen-induced, 
and ligand-independent ER transcriptional activity 
[33,34]. Additionally, PI3K and Ras contribute to the 
modulation of ER and transcription cofactors [35-45]. 
Th  e activation of ER by growth factor RTK signaling is 
reciprocated in a feed-forward fashion, whereby ER 
promotes the transcription of genes encoding receptor 
ligands, RTKs, and signaling adaptors [45-50]. Clinical 
evidence further suggests that ER may activate the PI3K 
pathway. For example, neoadjuvant treatment of patients 
bearing ER+ breast cancer with the AI letrozole reduces 
P-AKTS473, P-mTORS2448, and P-S6 tumor levels; these 
reductions have been shown to correlate with clinical 
response [51,52]. Emerging evidence also implicates 
estrogens in the rapid, non-genomic activation of PI3K 
via IGF-1R/insulin receptor (InsR), EGFR, Src, PI3K, and 
MEK [53-56].
PI3K pathway activation has been shown to confer 
anti-estrogen resistance in various experimental models, 
including in PTEN-deﬁ   cient cells, and in cells over-
expressing HER2, IGF-1R, or an activated mutant of 
AKT1 [33,44,54]. Tumor cells with acquired endocrine 
resistance have shown upregulation of IGF-1R, InsR, 
HER2, and EGFR levels as well as PI3K/AKT/mTOR 
activation [57-61]. Inhibition of the PI3K pathway 
reverses such anti-estrogen resistance. However, PI3K or 
AKT inhibition relieves feedback inhibition of the 
expression and activation of RTKs, which can contribute 
to drug resistance [17,25,26]. Interestingly, a recent study 
showed that in ER+ breast cancer cells treated with the 
PI3K/mTOR inhibitor BEZ235 or with PI3K siRNA, 
exogenous estradiol prevented drug- and siRNA-induced 
apoptosis [62]. Since most breast cancers that adapt to 
anti-estrogen therapy retain ER, these data imply that 
unopposed estrogen ligands may protect ER+ tumors 
from the therapeutic eﬀ  ects of PI3K inhibitors used as 
single agents.
Clinical evidence suggests that activation of PI3K via 
overexpression of HER2 or FGFR1, or loss of INPP4B 
also confers anti-estrogen resistance to patients with ER+ 
breast cancer [30-32,63,64]. Whether other mutations in 
the PI3K pathway correlate with anti-estrogen resistance 
remains to be determined. PIK3CA mutations occur in 
28 to 47% of ER+ breast cancers. Interestingly, such 
muta  tions correlate with good long-term outcome and 
lower PI3K and TORC1 activation as assessed by gene 
expression proﬁ  ling and immunohistochemistry (IHC) in 
patients bearing ER+ tumors [6,52,65-68]. Despite these 
ﬁ   ndings, preclinical evidence indicates that combined 
targeting of PI3K and ER is synergistic [69], suggesting 
that combinations of anti-estrogens and PI3K pathway 
inhibitors will be clinically more eﬀ   ective than anti-
estrogens alone.
Th  e correlations between PIK3CA mutations, good 
patient outcome, and low PI3K pathway activation 
(measured by gene expression proﬁ  ling and IHC) beg the 
need for alternative methods indicative of PI3K pathway 
activation to identify ER+ tumors at risk of recurrence. 
For example, a primary breast tumor gene expression 
signature of PTEN loss, derived from a comparison of 
PTEN-expressing versus PTEN-negative tumors by IHC, 
was predictive of poor relapse-free survival following 
tamoxifen, while PTEN status by IHC was not [8]. Breast 
cancers of the luminal A and luminal B molecular 
subtypes (based on gene expression proﬁ  ling) are typi-
cally ER+. However, luminal B tumors beneﬁ  t less from 
adjuvant anti-estrogen therapy [70]. Of note, a gene ex-
pres  sion signature of PI3K activation, based on tumor 
levels of a panel of phosphoproteins (for example, P-AKT, 
P-p70S6K) in ER+ tumors, was enriched in luminal B 
breast cancers [71]. Th   is suggests that luminal B tumors 
have higher PI3K activity, which may contribute to their 
lower response to anti-estrogens compared to luminal A 
tumors [72]. Similarly, we identiﬁ   ed a tumor protein 
signature of PI3K pathway activation that predicts poor 
outcome following adjuvant endocrine therapy [58]. 
Th   erefore, signatures of PI3K activation may complement 
mutational analyses for the identiﬁ   cation of high-risk, 
PI3K-driven, ER+ tumors.
Further rationale for combined inhibition of PI3K and 
ER comes from studies using inhibitors of TORC1 or 
HER2. In patients with ER+ tumors randomized to neo-
adjuvant letrozole with or without the TORC1 inhibitor 
everolimus for 4 months before surgery, the addition of 
everolimus increased clinical response and suppression 
of tumor cell proliferation [52]. In the TAMRAD study in 
patients with metastatic ER+ breast cancer who had 
progressed on an AI, the addition of everolimus to 
tamoxifen improved the rate of clinical beneﬁ  t, time-to-
progression, and disease-free survival compared to 
women receiving tamoxifen alone [73]. Most recently, 
results from the phase III trial BOLERO-2 showed that 
treatment with everolimus plus the AI exemestane 
provided a time-to-progression of 10.6 months compared 
to 4.1 months with the AI alone in post-menopausal 
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progressed on prior endocrine therapy [74].
Th  e ER and PI3K pathways appear to exist in an 
equilibrium, where tumors with low PI3K activation have 
Figure 2. Inhibition of phosphatidylinositol 3-kinase/mammalian target of rapamycin abrogates lapatinib resistance in HER2+ breast 
cancer cells. (a) BT-474 and SKBR3 cells were serum-starved for 3 days, then treated with or without 1 μM lapatinib or 250 nM BEZ235 for 2 
days. Cells were fi  xed, stained using the ApoBrdU kit (Phoenix Flow Systems), and analyzed by fl  ow cytometry. Cells were considered apoptotic 
if they exhibited sub-G1 levels by propidium iodide staining, and/or high fl  uorescein isothiocyanate (FITC)-bromodeoxyuridine (BrdU) labeling. 
Representative plots are shown, and the percentage of apoptotic cells (mean of triplicates ± standard deviation) is noted in each panel; blue, 
live; red, dead. (b) BT474 and SKBR3 cells were selected for long-term growth in the presence of 2 μM lapatinib to generate resistant cells [83]. 
Parental and lapatinib-resistant cells were treated with or without 250 nM BEZ235 in growth medium (lapatinib-resistant cells were maintained in 
2 μM lapatinib). Media and drugs were replenished every 2 to 3 days. Cell viability was measured after 5 to 6 days by WST1 assay (Roche). Data are 
presented as percentage parental control for each cell line, mean of triplicates ± standard deviation. *P < 0.05 by Bonferroni post-hoc test compared 
to parental control.
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dependence of these pathways is supported by studies 
showing that inhibition of HER2 with the antibody 
trastuzumab or the tyrosine kinase inhibitor lapatinib 
restores or upregulates ER levels or transcriptional activity 
in breast cancer cells and patient tumors. Furthermore, 
treatment with AIs or fulvestrant inhibits the growth of 
HER2+ tumors that had progressed on trastuzumab or 
lapatinib [75,76]. Th   ese data suggest that combined inhi-
bi  tion of ER and HER2, an RTK that potently activates 
PI3K, may provide more eﬀ  ective control of ER+/HER2+ 
tumors. Indeed, two clinical trials showed that the 
addition of trastuzumab or lapatinib to therapy with an 
AI increased progression-free survival and clinical 
beneﬁ  t compared to the AI alone [77,78].
PI3K alterations in HER2+ breast cancer
Most patients bearing breast cancers with ampliﬁ  cation 
or overexpression of HER2 beneﬁ   t from anti-HER2 
therapy. However, most patients with HER2+ metastatic 
disease eventually acquire resistance to trastuzumab, 
lapatinib, and the combination [79-81]. HER2 potently 
activates PI3K via heterodimerization with HER3, and 
other PI3K pathway activating mutations often coexist in 
HER2+ cancers (Table  1). Experimental and clinical 
evidence suggest that mutational activation of the PI3K 
pathway confers resistance to HER2-directed therapies, 
perhaps by providing an additional input to this pathway 
independent of HER2/HER3 dimers. HER2+ breast 
cancer cell lines are highly sensitive to PI3K and mTOR 
inhibitors before and after acquiring resistance to trastu-
zumab or lapatinib [22,82,83] (Figure  2). Th  ese data 
suggest that these drug-resistant cells remain PI3K-
dependent, and that patients with trastuzumab- and/or 
lapatinib-resistant disease would beneﬁ   t from PI3K 
pathway inhibitors.
Retrospective analyses of cohorts of patients with 
HER2+ metastatic breast cancer have shown that tumors 
harboring PIK3CA mutations and/or decreased levels of 
PTEN have a poor outcome following treatment with 
trastuzumab compared to HER2+ tumors with a ‘wild-
type’ PI3K pathway [84-87]. In addition, a neoadjuvant 
study in patients with HER2+ breast cancer showed that 
both alterations (PIK3CA mutations and PTEN loss) 
were associated with a statistically lower pathological 
complete response rate to trastuzumab with 
chemotherapy. However, tumors with decreased PTEN 
responded to neoadjuvant therapy with lapatinib 
followed by trastuzumab and chemotherapy [88]. Pend-
ing conﬁ  rmation of this report, these data suggest that 
PTEN-deﬁ  cient HER2+ cancer cells still rely heavily on 
upstream input from HER2 and, therefore, dual blockade 
of HER2 with trastuzumab and lapatinib is eﬀ  ective 
against HER2+/PTEN-deﬁ   cient breast cancers. A few 
studies suggest that combined targeting of HER2 and the 
PI3K pathway is superior to HER2-directed therapy 
alone. In patients who had progressed on trastuzumab 
and chemotherapy, the addition of the TORC1 inhibitor 
everolimus to trastuzumab and chemotherapy conferred 
a 19 to 44% objective response rate [89-91]. Preclinical 
studies also suggest that because of the reactivation of 
HER3 following inhibition of PI3K/AKT/TORC1 in 
HER2-overexpressing breast cancer cells, PI3K inhibitors 
should be given in combination with anti-HER2 therapy 
in patients with HER2 tumors [22,25,92]. At this time, 
patients with drug-resistant HER2+ breast cancer are a 
subgroup of intense focus in exploratory trials with PI3K 
pathway inhibitors.
PI3K pathway mutations in triple-negative breast 
cancer
Since ER, PR, and HER2 are established molecular 
markers associated with response to targeted therapies, 
ER-/PR-/HER2-negative cancers are loosely grouped as 
TNBCs. Such cancers occur in 10 to 15% of patients, are 
associated with earlier age at diagnosis, poor prognosis, 
and  BRCA1 mutations, and are more prevalent in 
African-American and Hispanic women [93]. By gene 
expression proﬁ  ling, TNBCs cluster separately from ER+ 
and HER2+ cancers, mainly within the basal-like 
molecular subtype. A recent analysis revealed that 
TNBCs can be divided into six subtypes [94]. Interest-
ingly, the ‘mesenchymal-like’ and ‘mesenchymal stem-
like’ subtypes exhibit enrichment for components of 
growth factor signaling pathways, including inositol 
phosphate metabolism. Growth of breast cancer cell lines 
classiﬁ  ed as ‘mesenchymal-like,’ ‘mesenchymal stem-like’, 
or ‘luminal androgen receptor subtype’ was inhibited by 
the PI3K/mTOR inhibitor BEZ235. Cell lines of the 
‘luminal androgen receptor subtype’ exhibit a high 
frequency of PIK3CA mutations. In contrast, PTEN 
status did not correlate with sensitivity to BEZ235. PTEN 
has functions outside of the PI3K pathway, including in 
DNA double-strand break repair. In addition, BRCA1 
mutations impair double-strand break repair and corre-
late with the presence of PTEN mutations [95], and 
PTEN knock-down has been shown to sensitize BRCA1-
mutant cancer cells to poly(ADP-ribose) polymerase 
(PARP) inhibition [96,97]. Th  us, it is conceivable that 
PTEN-deﬁ   cient cells may respond to combined PI3K/
PARP-directed therapy.
Th   e standard treatment for patients with TNBC 
includes mainly DNA-damaging chemotherapy. PI3K 
pathway mutations have been associated with resistance 
to such agents, likely by promoting cell survival. Also, 
DNA damage elicits DNA-dependent protein kinase-
mediated phosphorylation of AKT [98]. Preclinical 
studies in diverse cancer cell types have shown that PI3K 
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damaging agents [99-102]. Clinical trials are ongoing to 
test such drug combinations in patients with TNBC.
Conclusions
Somatic mutations in the PI3K pathway identify cancers 
with aberrant activation of, and potential dependence on, 
this signaling pathway. Th   ese attributes may be useful for 
the selection of patients for trials with PI3K inhibitors. 
Indeed, a recent analysis of patients with solid tumors 
enrolled in phase I trials with PI3K/AKT/mTOR inhibi-
tors showed a higher response rate among patients with 
PIK3CA-mutant versus wild-type PIK3CA cancers [103]. 
Th  is suggests that tumors with gain-of-function muta-
tions in the PI3K pathway depend on PI3K signaling, and 
this dependence can be exploited in patients with such 
cancers. Th   ere is increasing agreement that initial phase 
II eﬃ   cacy studies with PI3K inhibitors in patients with 
advanced disease should be enriched with, if not limited 
to, patients harboring mutations and/or activa  tion of this 
pathway. As with other targeted therapies, only a fraction 
of patients will likely beneﬁ   t from single-agent PI3K-
directed therapy. PI3K pathway inhibitors are being 
tested in human trials in combination with inhibitors of 
HER2, MEK, and ER. Early clinical data suggest that this 
strategy is feasible and that, as single agents, these drugs 
are well-tolerated. To determine if inhibition of PI3K 
confers a beneﬁ  t compared to standard targeted therapies 
alone will require randomized clinical trials.
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